The content on this site is intended for healthcare professionals only
Dr Marina Garassino speaks to ecancer about the TROPION-Lung 01 study presented at WCLC 2024.
The latest data from this study indicates that measuring TROP2 expression using quantitative continuous scoring can help predict clinical outcomes for patients with advanced or metastatic non-small cell lung cancer who are being treated with the TROP2 antibody-drug conjugate datopotamab deruxtecan.
The data revealed that patients testing positive for TROP2 showed better response to datopotamab deruxtecan compared to those receiving docetaxel in the TROPION-Lung01 phase III trial.
Read the full story here.
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Uncommon genetic aberrations NTRK, RET, NRG
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Updates on lung cancer from WCLC and ESMO 2023
